BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 16, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 28, 2003
View Archived Issues
Onyx, Bayer Start 9006 Phase III Program In Renal Cell Carcinoma
Onyx Pharmaceuticals Inc. and partner Bayer Corp. initiated a pivotal Phase III study in renal cell carcinoma with BAY 43-9006, a cancer candidate considered by some to be one of the most exciting products in development. (BioWorld Today)
Read More
Dynavax Enters IPO Ring; Aims To Go Public With $90M Offering
Read More
Mycobacterium Tuberculosis Plays Tag With Key Genes, Proteins, Now New LRG-47 Likely Drug Candidate
Read More
Remicade's Phase III Data Support Label Expansion In Spinal Arthritis
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More